Wechselwirkungen von Fluticason und Salmeterol

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (Fachinformation zu Abirateron, Warnhinweise und Vorsichtsmaßnahmen)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (Fachinformation zu Arsentrioxid, Boxed Warning (umrahmter Warnhinweis))

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (Fachinformation zu Axitinib, Warnhinweise und Vorsichtsmaßnahmen)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Baricitinib, Boxed Warning (umrahmter Warnhinweis))

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (Fachinformation zu Dronabinol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Gegenanzeigen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Etanercept, Boxed Warning (umrahmter Warnhinweis))

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (Fachinformation zu Imipramin, Arzneimittelwechselwirkungen)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Infliximab, Boxed Warning (umrahmter Warnhinweis))

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (Fachinformation zu Kokain, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (Fachinformation zu Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (Fachinformation zu Lovastatin, Gegenanzeigen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (Fachinformation zu Mitotan, Boxed Warning (umrahmter Warnhinweis))

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (Fachinformation zu Moexipril, Warnhinweise)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (Fachinformation zu Phenelzin, Gegenanzeigen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (Fachinformation zu Ribavirin, Boxed Warning (umrahmter Warnhinweis))

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (Fachinformation zu Rilpivirin, Gegenanzeigen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (Fachinformation zu Roflumilast, Warnhinweise und Vorsichtsmaßnahmen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (Fachinformation zu Sirolimus, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Fachinformation zu Somatropin, Arzneimittelwechselwirkungen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Tocilizumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Tofacitinib, Boxed Warning (umrahmter Warnhinweis))

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (Fachinformation zu Trandolapril, Warnhinweise)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (Fachinformation zu Tranylcypromin, Boxed Warning (umrahmter Warnhinweis))

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Fachinformation zu Tretinoin, Boxed Warning (umrahmter Warnhinweis))

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Upadacitinib, Boxed Warning (umrahmter Warnhinweis))

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (Fachinformation zu Acetylsalicylsäure, Warnhinweise)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Fachinformation zu Aclidiniumbromid, Arzneimittelwechselwirkungen)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Fachinformation zu Afatinib, Warnhinweise und Vorsichtsmaßnahmen)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (Fachinformation zu Albendazol, Warnhinweise und Vorsichtsmaßnahmen)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (Fachinformation zu Alemtuzumab, Warnhinweise und Vorsichtsmaßnahmen)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (Fachinformation zu Alendronsäure, Warnhinweise und Vorsichtsmaßnahmen)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (Fachinformation zu Aliskiren, Warnhinweise und Vorsichtsmaßnahmen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Fachinformation zu Alogliptin und Metformin, Arzneimittelwechselwirkungen)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (Fachinformation zu Alpelisib, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (Fachinformation zu Amphotericin B, Arzneimittelwechselwirkungen)

Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (Fachinformation zu Atomoxetin, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Belladonna und Opium, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (Fachinformation zu Benralizumab, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Since β 1 -selectivity is not absolute and is inversely related to dose, the lowest possible dose of betaxolol should be used (5 to 10 mg once daily) and a bronchodilator should be made available. (Fachinformation zu Betaxolol, Warnhinweise)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (Fachinformation zu Bictegravir, Emtricitabin und Tenofoviralafenamid, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Fachinformation zu Bortezomib, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Buprenorphin, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Buprenorphin und Naloxon, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Butorphanol, Warnhinweise)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (Fachinformation zu Cefoxitin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Celecoxib, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Ciprofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (Fachinformation zu Cladribin, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Codein, Warnhinweise und Vorsichtsmaßnahmen)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (Fachinformation zu Cytarabin, Warnhinweise)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (Fachinformation zu Daptomycin, Warnhinweise und Vorsichtsmaßnahmen)

…darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan,… (Fachinformation zu Deferasirox, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Fachinformation zu Denosumab, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (Fachinformation zu Desogestrel und Ethinylestradiol, Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac und Misoprostol, Warnhinweise und Vorsichtsmaßnahmen)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Diflunisal, Warnhinweise)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (Fachinformation zu Digoxin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (Fachinformation zu Doxapram, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (Fachinformation zu Dupilumab, Warnhinweise und Vorsichtsmaßnahmen)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Fachinformation zu Elexacaftor, Tezacaftor und Ivacaftor, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Fachinformation zu Erlotinib, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Sympathomimetic drugs: Dose adjustment needed (7) (Fachinformation zu Esmolol, Arzneimittelwechselwirkungen)

Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (Fachinformation zu Estradiol, Vorsichtsmaßnahmen)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (Fachinformation zu Estradiol und Dienogest, Arzneimittelwechselwirkungen)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (Fachinformation zu Estradiol und Norethisteron, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Etodolac, Warnhinweise)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (Fachinformation zu Etravirin, Arzneimittelwechselwirkungen)

The amount of both steroids should be considered in the choice of an oral contraceptive. (Fachinformation zu Etynodioldiacetat und Ethinylestradiol, Warnhinweise)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Fenoprofen, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (Fachinformation zu Fingolimod, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Flurbiprofen, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Fachinformation zu Glycerolphenylbutyrat, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Fachinformation zu Haloperidol, Arzneimittelwechselwirkungen)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (Fachinformation zu Hydralazin, Warnhinweise)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Chlorphenamin, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Homatropin, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Ibuprofen, Warnhinweise)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Paracetamol, Warnhinweise)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydromorphon, Warnhinweise und Vorsichtsmaßnahmen)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (Fachinformation zu Ibandronsäure, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Ibuprofen und Famotidin, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Indometacin, Warnhinweise und Vorsichtsmaßnahmen)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (Fachinformation zu Ivermectin, Warnhinweise)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (Fachinformation zu Ketamin, Warnhinweise und Vorsichtsmaßnahmen)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Fachinformation zu Ketoprofen, Warnhinweise und Vorsichtsmaßnahmen)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Ketorolac, Warnhinweise und Vorsichtsmaßnahmen)

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (Fachinformation zu Konjugierte Estrogene, Vorsichtsmaßnahmen)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (Fachinformation zu Konjugierte Estrogene und Bazedoxifen, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Levofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (Fachinformation zu Levonorgestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Levorphanol, Warnhinweise)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (Fachinformation zu Levothyroxin, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (Fachinformation zu Margetuximab, Warnhinweise und Vorsichtsmaßnahmen)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (Fachinformation zu Medroxyprogesteron, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Mefenaminsäure, Warnhinweise und Vorsichtsmaßnahmen)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (Fachinformation zu Megestrol, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Meloxicam, Warnhinweise und Vorsichtsmaßnahmen)

Decrease corticosteroids gradually, if appropriate. (Fachinformation zu Mepolizumab, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (Fachinformation zu Methazolamid, Arzneimittelwechselwirkungen)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (Fachinformation zu Methotrexat, Arzneimittelwechselwirkungen)

If not, corticosteroids may be given and other causes of anemia should be considered. (Fachinformation zu Methyldopa, Warnhinweise)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Bronchodilators, including beta 2 -agonists, should be readily available or administered concomitantly [see Dosage and Administration (2) ]. (Fachinformation zu Metoprolol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

This can be corrected by giving appropriate doses of corticosteroids. (Fachinformation zu Metyrapon, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Inhaled corticosteroid may be reduced gradually. (Fachinformation zu Montelukast, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Morphin, Warnhinweise und Vorsichtsmaßnahmen)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Moxifloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Nabumeton, Warnhinweise)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Nalbuphin, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen und Esomeprazol, Warnhinweise und Vorsichtsmaßnahmen)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (Fachinformation zu Natalizumab, Warnhinweise und Vorsichtsmaßnahmen)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Fachinformation zu Natriumphenylacetat und Natriumbenzoat, Arzneimittelwechselwirkungen)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (Fachinformation zu Natriumphenylbutyrat, Arzneimittelwechselwirkungen)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (Fachinformation zu Ocrelizumab, Warnhinweise und Vorsichtsmaßnahmen)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Ofloxacin, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oliceridin, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Fachinformation zu Omalizumab, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Oxaprozin, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oxycodon, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oxycodon und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oxymorphon, Warnhinweise und Vorsichtsmaßnahmen)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Fachinformation zu Pamidronsäure, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Paracetamol und Codein, Warnhinweise)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (Fachinformation zu Pasireotid, Warnhinweise und Vorsichtsmaßnahmen)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Fachinformation zu Penicillamin, Warnhinweise)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Pentazocin und Naloxon, Warnhinweise)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Pethidin, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (Fachinformation zu Ponesimod, Warnhinweise und Vorsichtsmaßnahmen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Promethazin und Codein, Warnhinweise und Vorsichtsmaßnahmen)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (Fachinformation zu Propofol, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (Fachinformation zu Risedronsäure, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (Fachinformation zu Rocuronium, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Salsalat, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (Fachinformation zu Sotalol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Sulindac, Warnhinweise)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Fachinformation zu Suxamethonium, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Tapentadol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Fachinformation zu Temsirolimus, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (Fachinformation zu Teriparatid, Warnhinweise und Vorsichtsmaßnahmen)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Fachinformation zu Tesamorelin, Arzneimittelwechselwirkungen)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (Fachinformation zu Testosteron, Warnhinweise und Vorsichtsmaßnahmen)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (Fachinformation zu Theophyllin, Warnhinweise)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Fachinformation zu Tiotropiumbromid, Arzneimittelwechselwirkungen)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (Fachinformation zu Tolcapon, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Tolmetin, Warnhinweise)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Tramadol, Warnhinweise und Vorsichtsmaßnahmen)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Tramadol und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (Fachinformation zu Warfarin, Arzneimittelwechselwirkungen)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (Fachinformation zu Zanamivir, Warnhinweise und Vorsichtsmaßnahmen)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (Fachinformation zu Zenocutuzumab, Warnhinweise und Vorsichtsmaßnahmen)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (Fachinformation zu Zoledronsäure, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (Fachinformation zu Acebutolol, Warnhinweise)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Fachinformation zu Alteplase, Warnhinweise und Vorsichtsmaßnahmen)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (Fachinformation zu Amikacin, Warnhinweise und Vorsichtsmaßnahmen)

If paradoxical bronchospasm occurs following dosing with inhaled fluticasone propionate/salmeterol medicines, it should be treated immediately with an inhaled, short-acting bronchodilator; inhaled fluticasone propionate/salmeterol medicines should be discontinued immediately; and alternative therapy should be instituted. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Fachinformation zu Ampicillin, Warnhinweise)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (Fachinformation zu Bempedoinsäure, Warnhinweise und Vorsichtsmaßnahmen)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (Fachinformation zu Benzylpenicillin (Penicillin G), Warnhinweise)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (Fachinformation zu Bevacizumab, Warnhinweise und Vorsichtsmaßnahmen)

A beta 2 agonist (bronchodilator) should be made available. (Fachinformation zu Bisoprolol, Warnhinweise)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (Fachinformation zu Bromocriptin, Arzneimittelwechselwirkungen)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Fachinformation zu Busulfan, Warnhinweise)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (Fachinformation zu Calcitriol, Arzneimittelwechselwirkungen)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefaclor, Warnhinweise)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefadroxil, Warnhinweise und Vorsichtsmaßnahmen)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefdinir, Warnhinweise)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefotetan, Warnhinweise)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefprozil, Warnhinweise)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Ceftazidim, Warnhinweise)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (Fachinformation zu Ceftriaxon, Warnhinweise und Vorsichtsmaßnahmen)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (Fachinformation zu Chinin, Arzneimittelwechselwirkungen)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (Fachinformation zu Clofarabin, Warnhinweise und Vorsichtsmaßnahmen)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (Fachinformation zu Clomifen, Warnhinweise)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Fluticasone Propionate/Salmeterol MDPI continues, but at times therapy with Fluticasone Propionate/Salmeterol MDPI may need to be interrupted. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (Fachinformation zu Corticotropin, Warnhinweise und Vorsichtsmaßnahmen)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Dapagliflozin und Metformin, Arzneimittelwechselwirkungen)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (Fachinformation zu Droperidol, Arzneimittelwechselwirkungen)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (Fachinformation zu Drospirenon und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Fluticasone Propionate/Salmeterol MDPI continues, but at times therapy with Fluticasone Propionate/Salmeterol MDPI may need to be interrupted. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Empagliflozin und Metformin, Arzneimittelwechselwirkungen)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Etonogestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

Steroids may or may not be effective in controlling these hemolytic episodes. (Fachinformation zu Fludarabin, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (Fachinformation zu Guselkumab, Warnhinweise und Vorsichtsmaßnahmen)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (Fachinformation zu Humaninsulin (Normalinsulin), Warnhinweise und Vorsichtsmaßnahmen)

If paradoxical bronchospasm occurs following dosing with inhaled fluticasone propionate/salmeterol medicines, it should be treated immediately with an inhaled, short-acting bronchodilator; inhaled fluticasone propionate/salmeterol medicines should be discontinued immediately; and alternative therapy should be instituted. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Beta blockers antagonize the bronchodilator effect of beta-receptor agonists. (Fachinformation zu Labetalol, Arzneimittelwechselwirkungen)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Linagliptin und Metformin, Arzneimittelwechselwirkungen)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (Fachinformation zu Melphalan, Warnhinweise)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Metformin, Arzneimittelwechselwirkungen)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (Fachinformation zu Methohexital, Warnhinweise)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Fluticasone Propionate/Salmeterol MDPI continues, but at times therapy with Fluticasone Propionate/Salmeterol MDPI may need to be interrupted. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Norelgestromin und Ethinylestradiol, Arzneimittelwechselwirkungen)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (Fachinformation zu Norethisteron und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Norgestimat und Ethinylestradiol, Arzneimittelwechselwirkungen)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Norgestrel und Ethinylestradiol, Vorsichtsmaßnahmen)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (Fachinformation zu Oxacillin, Warnhinweise)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Fachinformation zu Phenoxymethylpenicillin (Penicillin V), Warnhinweise)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Pioglitazon und Metformin, Arzneimittelwechselwirkungen)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Propylthiouracil, Warnhinweise)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Raloxifen, Arzneimittelwechselwirkungen)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (Fachinformation zu Rituximab, Warnhinweise und Vorsichtsmaßnahmen)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Saxagliptin und Metformin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Sitagliptin und Metformin, Arzneimittelwechselwirkungen)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (Fachinformation zu Tenecteplase, Warnhinweise und Vorsichtsmaßnahmen)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Thiamazol, Warnhinweise)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (Fachinformation zu Tobramycin, Arzneimittelwechselwirkungen)

If paradoxical bronchospasm occurs following dosing with inhaled fluticasone propionate/salmeterol medicines, it should be treated immediately with an inhaled, short-acting bronchodilator; inhaled fluticasone propionate/salmeterol medicines should be discontinued immediately; and alternative therapy should be instituted. (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (Fachinformation zu Ustekinumab, Warnhinweise und Vorsichtsmaßnahmen)

Kortikosteroide wie Prednison verringern die Calciumaufnahme und beeinträchtigen den Vitamin-D-Stoffwechsel, was zum Knochenschwund beiträgt. (NIH Office of Dietary Supplements, Vitamin D)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)